<DOC>
	<DOCNO>NCT01489670</DOCNO>
	<brief_summary>This study ass efficacy , safety , tolerability persistence use Lumigan ® 0.01 % patient diagnosed primary open-angle glaucoma ocular hypertension treat per routine clinical practice .</brief_summary>
	<brief_title>Observational Study Lumigan® 0.01 % Treatment Patients With Primary Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis primary openangle glaucoma ocular hypertension Lumigan® 0.01 % prescribe either monotherapy adjunctive betablocker therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>